Chinese biotech firm uses DNA to discover new drugs
CGTN, By Wei Lynn Tang
HitGen Inc., a Chengdu-based biotechnology company that has listed on China's Science and Technology Innovation Board on April 16, raising some 118 million U.S. dollars.
According to the company's listing prospectus, 75 percent of its listing net proceeds will be used for a new molecular design, construction, and application platform construction project, with the remaining funds for a new drugs research and development project.
According to the company's listing prospectus, 75 percent of its listing net proceeds will be used for a new molecular design, construction, and application platform construction project, with the remaining funds for a new drugs research and development project.
Li Jin, chairman and CEO of HitGen, said the company's top priority is to continue to invest in its core technology – the DEL technology – to make progress in its drug discovery programs.